Insider Selling: Vaxcyte, Inc. (NASDAQ:PCVX) CEO Sells 2,366 Shares of Stock

Vaxcyte, Inc. (NASDAQ:PCVX) CEO Grant Pickering sold 2,366 shares of Vaxcyte stock in a transaction on Monday, December 9th. The shares were sold at an average price of $92.25, for a total value of $218,263.50. Following the completion of the transaction, the chief executive officer now owns 136,215 shares of the company’s stock, valued at approximately $12,565,833.75. The trade was a 1.71 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Grant Pickering also recently made the following trade(s):

• On Monday, December 2nd, Grant Pickering sold 15,000 shares of Vaxcyte stock. The stock was sold at an average price of $92.45, for a total transaction of $1,386,750.00.
• On Thursday, November 7th, Grant Pickering sold 2,366 shares of Vaxcyte stock. The shares were sold at an average price of $103.89, for a total transaction of $245,803.74.
• On Friday, November 1st, Grant Pickering sold 15,000 shares of Vaxcyte stock. The stock was sold at an average price of $106.82, for a total value of $1,602,300.00.
• On Monday, October 7th, Grant Pickering sold 7,098 shares of Vaxcyte stock. The stock was sold at an average price of $109.21, for a total value of $775,172.58.

Vaxcyte Stock Performance

NASDAQ PCVX traded down $1.63 during trading hours on Tuesday, reaching $90.43. 896,067 shares of the company’s stock were exchanged, compared to its average volume of 904,060. The company has a market capitalization of $11.27 billion, a price-to-earnings ratio of -20.07 and a beta of 0.94. The company’s 50-day moving average is $103.01 and its two-hundred day moving average is $91.26. Vaxcyte, Inc. has a one year low of $53.83 and a one year high of $121.06.

Vaxcyte (NASDAQ:PCVX) last announced its earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.27. During the same quarter last year, the business earned ($0.91) earnings per share. Research analysts predict that Vaxcyte, Inc. will post -4.14 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Vaxcyte

Large investors have recently bought and sold shares of the company. Riverview Trust Co bought a new stake in shares of Vaxcyte in the third quarter worth $27,000. Fifth Third Bancorp bought a new stake in Vaxcyte during the 2nd quarter worth about $35,000. Blue Trust Inc. boosted its stake in shares of Vaxcyte by 33.5% during the 3rd quarter. Blue Trust Inc. now owns 371 shares of the company’s stock worth $42,000 after buying an additional 93 shares during the last quarter. J.Safra Asset Management Corp grew its holdings in shares of Vaxcyte by 649.4% in the 2nd quarter. J.Safra Asset Management Corp now owns 607 shares of the company’s stock valued at $46,000 after acquiring an additional 526 shares in the last quarter. Finally, Quest Partners LLC bought a new stake in Vaxcyte during the second quarter worth about $70,000. Institutional investors and hedge funds own 96.78% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. Bank of America upped their target price on shares of Vaxcyte from $101.00 to $140.00 and gave the company a “buy” rating in a research report on Wednesday, September 4th. Mizuho lifted their target price on shares of Vaxcyte from $113.00 to $163.00 and gave the stock an “outperform” rating in a report on Tuesday, September 10th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vaxcyte in a research report on Wednesday, November 6th. Leerink Partners raised their price target on Vaxcyte from $106.00 to $153.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 3rd. Finally, Jefferies Financial Group lifted their price objective on Vaxcyte from $108.00 to $129.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Vaxcyte presently has an average rating of “Buy” and a consensus target price of $147.50.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.